Navigation Links
Patton Boggs Wins Landmark Insurance Case for Client

WASHINGTON, Feb. 26 /PRNewswire/ -- A recent decision issued by the U.S. District Court for the Southern District of New York could have significant implications for the insurance industry. The February 13 ruling from U.S. District Judge Richard J. Holwell clarifies a decision the court entered two months earlier establishing that Texas law requires issuers of directors & officers (D&O) liability policies to advance defense costs incurred in connection with covered and non-covered causes of action interposed in the same lawsuit.

In an opinion dated December 19, 2008, Judge Holwell ruled that a lawsuit against Uncle Julio's restaurant chain contained a covered cause of action ("breach of fiduciary duty") and an excluded cause of action ("breach of contract"). Judge Holwell further ruled that Travelers Insurance, the issuer of Uncle Julio's D&O policy, was not only required to advance defense costs allocable to the covered cause of action, but also any defense costs that might be allocable to the non-covered cause of action. The insurer then moved for clarification of the bases for this latter aspect of the December 2008 ruling.

Judge Holwell clarified his earlier ruling in the February 13 opinion and agreed with the argument put forth by Patton Boggs senior litigation partner, John W. Schryber that the policy required advances of defense costs incurred in connection with a "Claim," and "the policy's definition of Claim ... clearly contemplates the equivalence of the word 'lawsuit' ... ." "Under this interpretation," Judge Holwell held, the insurer's duty to advance extends to "the entire lawsuit."

By operation of these rulings, the insured stands to recover in excess of $1 million for the insurer's breach of its duty to advance defense costs.

Mr. Schryber, who argued the case, stated: "For years, D&O insurers have sought to impose 'allocation' conditions on policyholders who purchased D&O policies without any allocation clause. This ruling should bring an end to the insurers' practice of seeking allocation under a policy that does not contain an allocation clause."

Patton Boggs LLP

Based in Washington DC, Patton Boggs is a national leader in public policy, litigation, and business law, and is well known for its deep bipartisan roots in the national political arena. The firm's core practice areas are Public Policy and Regulatory, Litigation, Business, and Intellectual Property. With offices in Northern Virginia, New Jersey, New York, Dallas, Denver, Anchorage, and internationally in Doha, Qatar and Abu Dhabi, UAE, our more than 600 lawyers and professionals provide comprehensive, practical, and cost-effective legal counsel to clients around the globe. For more information, visit us at To receive press releases from Patton Boggs, please contact Rebecca Carr at

SOURCE Patton Boggs LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Landmark Policy Report: Many Cancers Could Be Prevented Across the Globe
2. Landmark Report: Many Cancers Could be Prevented
3. Update on Landmark Study on Single-Payer as Economic Stimulus
4. Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative
5. Landmark Trial Provides Vital Information for Cardiac Disease Treatment
6. Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies Lives
7. Landmark textbook on strokes in children and young adults updated in second edition
8. Hope for Lung Cancer Research Dollars in California: The Bonnie J. Addario Lung Cancer Foundation (BJALCF) Applauds Landmark Legislation to Push through Funding for Lung Cancer Research in California
9. Coalition for Pulmonary Fibrosis Celebrates Landmark Year for Awareness, Advocacy, Research
10. First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients
11. Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: